Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
574 articles about Emergent BioSolutions
-
Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial
3/21/2007
-
Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise
3/15/2007
-
Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference
3/5/2007
-
Emergent BioSolutions Delivers Approximately 1 Million Doses Of BioThrax(R) Ahead Of Schedule To U.S. Department of Health and Human Services For Strategic National Stockpile
2/23/2007
-
The Day In Review: Allergan Inc. Expands Obesity Franchise
2/22/2007
-
FDA Grants Fast Track Designation To Emergent BioSolutions' BioThrax(R) For Post-Exposure Prophylaxis Against Anthrax Infection
2/12/2007
-
Emergent BioSolutions To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference
1/30/2007
-
Emergent BioSolutions Announces Expected 2006 Total Revenue Of Approximately $150 Million
1/8/2007
-
National Institutes of Health (NIH) To Sponsor Clinical Trial For Emergent BioSolutions' Group B Streptococcus Vaccine Candidate
12/21/2006
-
Emergent BioSolutions To Present At JPMorgan Healthcare Conference
12/21/2006
-
Emergent BioSolutions Applauds Passage And Signing Of BARDA Legislation
12/20/2006
-
Emergent BioSolutions Delivers Over 3 Million Doses Of BioThrax(R) To U.S. Department of Health And Human Services For Strategic National Stockpile
12/14/2006
-
Emergent BioSolutions Celebrates Initial Public Offering; CEO To Ring Opening Bell On The NYSE
11/21/2006
-
IPO Watch: Emergent BioSolutions Makes Anthrax Vaccine
11/15/2006
-
Emergent BioSolutions Announces Pricing Of Its Initial Public Offering
11/15/2006
-
Emergent BioSolutions Awarded Two Grants From NIAID To Support Development Of Anthrax Immune Globulin Therapeutic
8/31/2006
-
U.S. Department Of Homeland Security Certifies BioThrax(R) As An Approved Product For Homeland Security
8/29/2006
-
The Week In Review: Strong Gain; Stronger Breadth
8/21/2006
-
Emergent BioSolutions Files For $86 Million IPO
8/15/2006
-
Emergent BioSolutions Expands Presence In Germany; Acquires Vivacs GmbH Along With Rights To Modified Vaccinia Virus Ankara (MVA) Strain And Monoclonal Vector Technology Platform (MVAtor(TM))
8/3/2006